Frequent co-occurrence of the TATA box mutation associated with Gilbert's syndrome (UGT1A1*28) with other polymorphisms of the UDP-glucuronosyltransferase-1 locus (UGT1A6*2 and UGT1A7*3) in Caucasians and Egyptians

Biochemical Pharmacology

Volumn 65, Issue 9, 2003, Pages 1521-1527

  Köhle, Christoph ^a   Möhrle, Bernd ^a   Münzel, Peter A ^a   Schwab, Matthias ^b   Wernet, Dorothee ^c   Badary, Osama A ^d   Bock, Karl Walter ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^d Al Azhar University   (Egypt)

Author keywords

Genotype frequencies; Gilbert's syndrome; Haplotype frequencies; UGT1 polymorphisms

Indexed keywords

GLUCURONOSYLTRANSFERASE;

ALLELE; ARTICLE; CASE REPORT; CAUCASIAN; DISEASE ASSOCIATION; EGYPT; ENERGY TRANSFER; ENZYME POLYMORPHISM; FEMALE; FLUORESCENCE; GENE MUTATION; GENOTYPE; GILBERT DISEASE; HAPLOTYPE; HUMAN; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; TATA BOX;

EID: 17044450136     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(03)00074-1     Document Type: Article

References (27)

1. Nebert D.W., Ingelman-Sundberg M., Daly A.K. Genetic epidemiology of environmental toxicity and cancer susceptibility: human allelic polymorphisms in drug metabolizing enzyme genes, their functional importance, and nomenclature issues. Drug Metab. Rev. 31:1999;467-487.
2. Bosma P.J., Roy Chowdhury J., Bakker C., Gantla S., de Boer A., Oostra B.A., Lindhout D., Tytgat G.N., Jansen P.L., Oude Elferink R.P., Roy Chowdhury N. The genetic basis of the reduced expression of bilirubin UDP glucuronosyltransferase 1 in Gilbert's syndrome. N. Engl. J. Med. 333:1995;1171-1175.
3. Monaghan G., Ryan M., Seddon R., Hume R., Burchell B. Genetic variation in bilirubin UPD glucuronosyltransferase gene promoter and Gilbert's syndrome. Lancet. 347:1996;578-581.
4. Raijmakers M.T., Jansen P.L., Steegers E.A., Peters W.H. Association of human liver bilirubin UDP-glucuronyltransferase activity with a polymorphism in the promoter region of the UGT1A1 gene. J. Hepatol. 33:2000;348-351.
5. Ando Y., Saka H., Asai G., Sugiura S., Shimokata K., Kamataki T. UGT1A1 genotypes and glucuronidation of SN 38 the active metabolite of irinotecan. Ann. Oncol. 9:1998;845-847.
6. Innocenti F., Iyer L., Ratain M.J. Pharmacogenetics of anticancer agents: lessons from amonafide and irinotecan. Drug Metab. Dispos. 29:2001;596-600.
7. Ciotti M., Marrone A., Potter C., Owens I.S. Genetic polymorphism in the human UGT1A6 (planar phenol) UDP-glucuronosyltransferase: pharmacological implications. Pharmacogenetics. 7:1997;485-495.
8. Bigler J., Whitton J., Lampe J.W., Fosdick L., Bostick R.M., Potter J.D. CYP2C9 and UGT1A6 genotypes modulate the protective effect of aspirin on colon adenoma risk. Cancer Res. 61:2001;3566-3569.
9. Guillemette C., Ritter J.K., Auyeung D.J., Kessler F.K., Housman D.E. Structural heterogeneity at the UDP-glucuronosyltransferase 1 locus: functional consequences of three novel missense mutations in the human UGT1A7 gene. Pharmacogenetics. 10:2000;629-644.
10. Tukey R.H., Strassburg C.P. Genetic multiplicity of the human UDP-glucuronosyltransferases and regulation in the gastrointestinal tract. Mol. Pharmacol. 59:2001;405-414.
11. Vogel A., Kneip S., Barut A., Ehmer U., Tukey R.H., Manns M.P., Strassburg C.P. Genetic link of hepatocellular carcinoma with polymorphisms of the UDP glucuronosyltransferase UGT1A7 gene. Gastroenterology. 121:2001;1136-1144.
12. Zheng Z., Park J.Y., Guillemette C., Schantz S.P., Lazarus P. Tobacco carcinogen-detoxifying enzyme UGT1A7 and its association with orolaryngeal cancer risk. J. Natl. Cancer Inst. 93:2001;1411-1418.
13. Gong Q.H., Cho J.W., Huang T., Potter C., Gholami N., Basu N.K., Kubota S., Carvalho S., Pennington M.W., Owens I.S., Popescu N.C. Thirteen UDPglucuronosyltransferase genes are encoded at the human UGT1 gene complex locus. Pharmacogenetics. 11:2001;357-368.
14. Lampe J.W., Bigler J., Horner N.K., Potter J.D. UDP-glucuronosyltransferase (UGT1A1*28 and UGT1A6*2) polymorphisms in Caucasians and Asians: relationships to serum bilirubin concentrations. Pharmacogenetics. 9:1999;341-349.
15. Borlak J., Thum T., Landt O., Erb K., Hermann R. Molecular diagnosis of a familial nonhemolytic hyperbilirubinemia (Gilbert's Syndrome) in healthy subjects. Hepatology. 32:2000;792-795.
16. Schneider S, Roessli D, Excoffier L. ARLEQUIN ver. 2.000: a software for population genetics data analysis. University of Geneva, Switzerland: Genetics and Biometry Laboratory.
17. Excoffier L., Slatkin M. Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population. Mol. Biol. Evol. 12:1995;921-927.
18. Slatkin M., Excoffier L. Testing for linkage disequilibrium in genotypic data using expectation-maximization algorithm. Heredity. 76:1996;377-383.
19. Hall D., Ybazeta D., Destro-Bisol G., Petzl-Erler M.L., Di Rienzo A. Variability at the uridine diphosphate glucuronosyltransferase 1A1 promoter in human populations and primates. Pharmacogenetics. 9:1999;591-599.
20. Beutler E., Gelbart T., Demina A. Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc. Natl. Acad. Sci. U.S.A. 95:1998;8170-8174.
21. Stocker R., Yamamoto Y., McDonagh A.F., Glazer A.N., Ames B.N. Bilirubin is an antioxidant of possible physiological importance. Science. 235:1987;1043-1046.
22. Baranano D.E., Rao M., Ferris C.D., Snyder S.H. Biliverdin reductase: a major physiologic cytoprotectant. Proc. Natl. Acad. Sci. U.S.A. 99:2002;16093-16098.
23. Vogel A., Ehmer U., Barut A., Kneip S., Manns M.P., Strassburg C.P. Gene-environmental interaction: polymorphisms of the UDP-glucuronosyltransferase UGT1A7 gene in gastrointestinal cancer. Gastroenterology. 122(Suppl.):2002;W1248.
24. Ockenga J., Vogel A., Teich N., Keim V., Manns M.P., Strassburg C.P. Polymorphisms of the UDP-glucuronosyltransferase UGT1A7 gene as a risk factor in chronic pancreatitis and pancreatitic cancer. Gastroenterology. 122(Suppl.):2002;W1088.
25. Ando Y., Saka H., Ando M., Sawa T., Muro K., Ueoka H., Yokoyama A., Saitoh S., Shimokata K., Hasegawa Y. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res. 60:2000;6921-6926.
26. Tukey R.H., Strassburg C.P., Mackenzie P.I. Pharmacogenomics of human UDP-glucuronosyltransferases and irinotecan toxicity. Mol. Pharmacol. 62:2002;446-450.
27. Gagne J.F., Montminy V., Belanger P., Journault K., Gaucher G., Guillemette C. Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38). Mol. Pharmacol. 62:2002;608-617.